Treatment for MCI
Author:
- 27 May 2008
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 70 (22) , 2020-2021
Abstract
Whatever MCI is, it is surely a prevalent, important clinical problem. In the therapeutic age of AD that began 15 years ago, more individuals seek evaluation at early stages of impairment. The clinician may be uncertain of the best label (though MCI often seems preferable to very early AD; it is less foreboding, more palatable, gentler), but a number of interventions seem appropriate and are widely practiced. The most important is education of patient and family regarding the risks, appropriate safety measures (limiting or halting driving, limiting some responsibilities, providing supervision), and planning (occupational, health, financial, legal, care). Clinicians commonly offer general recommendations …Keywords
This publication has 4 references indexed in Scilit:
- Safety and efficacy of galantamine in subjects with mild cognitive impairmentNeurology, 2008
- Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx studyThe Lancet Neurology, 2007
- Vitamin E and Donepezil for the Treatment of Mild Cognitive ImpairmentNew England Journal of Medicine, 2005
- A Randomized, Double-Blind, Study of Rofecoxib in Patients with Mild Cognitive ImpairmentNeuropsychopharmacology, 2005